Results 91 to 100 of about 29,860 (191)

Improvement in Outcomes with a New Bedaquiline-based Regimen in Postoperative Cases of Drug-resistant Tuberculosis of the Spine: A Case Series [PDF]

Journal of Clinical and Diagnostic Research
The incidence of drug-resistant strains of Tuberculosis (TB) is rising at an alarming rate. With the emergence of newer drug-resistant strains, managing the disease with existing antitubercular agents is becoming increasingly difficult. Few studies exist
Soutrik Kundu, Sarvan Singh
doaj   +1 more source

Online service for interpretation of the resistance prediction results to bedaquiline by the molecular data

Acta Biomedica Scientifica
Background. Bedaquiline is a new and promising anti-tuberculosis drug, but longterm use requires resistance. This is due to mutations in the atpE and mmpR genes in M.
V. V. Sinkov, I. G. Kondratov, O. B. Ogarkov, S. N. Zhdanova, A. P. Noskov, P. A. Khromova, E. A. Orlova, A. V. Labygina, L. V. Rychkova, L. I. Kolesnikova   +9 more
doaj   +1 more source

New synthetic approaches towards analogues of bedaquiline

, 2016
Multi-drug resistant tuberculosis (MDR-TB) is of growing global concern and threatens to undermine increasing efforts to control the worldwide spread of tuberculosis (TB). Bedaquiline has recently emerged as a new drug developed to specifically treat MDR-
L Barbaro (13653031), JB Baell (11036820), DL Priebbenow (15870668)   +2 more
core  

Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa

, 2018
Optimal treatment regimens for patients with extensively drug-resistant tuberculosis (XDR-TB) remain unclear. Long-term prospective outcome data comparing XDR-TB regimens with and without bedaquiline from an endemic setting are lacking.We prospectively ...
Rob Warren, Aliasgar Esmail, Mohammed Fadul, Olatunde Olayanju, Phindile Gina, Suzette Oelofse, Elize Pietersen, Keertan Dheda, Jason Limberis   +8 more
core   +1 more source

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline

Therapeutics and Clinical Risk Management, 2014
Eric Leibert, Mauricio Danckers, William N Rom Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, New York University School of Medicine, New York, NY, USA Abstract: Mycobacterium tuberculosis develops spontaneous ...
Leibert E, Danckers M, Rom WN
doaj  

Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Background: Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and leads to serious complications if left untreated. Some strains of Mycobacterium tuberculosis are multi-drug resistant and require treatment with newer drugs ...
Obaid Ur Rehman, Eeshal Fatima, Abraish Ali, Umar Akram, Abdulqadir Nashwan, Faryal Yunus   +5 more
doaj   +1 more source

Primary bedaquiline-resistant tuberculosis in an Afghan migrant to Switzerland: Diagnostic and treatment challenges in a high-resource setting

International Journal of Infectious Diseases
Bedaquiline, classified as a WHO 2019 group A drug, is a core component of BPaLM, revolutionizing the treatment of MDR/RR tuberculosis (TB). Since 2015, however, concerns about acquired and primary bedaquiline resistance have emerged.We report a ...
Nasstasja Wassilew, Anna Eichenberger, Cornelia Staehelin, Carlo Casanova, Bettina Schulthess, Gunar Günther   +5 more
doaj   +1 more source

Bedaquiline [PDF]

, 2020
openaire   +1 more source

FDA Approves New Tuberculosis Drug: Bedaquiline (Sirturo®)

, 2019
Tuberculosis (TB), caused by the acid-fast bacilli (AFB) Mycobacterium tuberculosis, is an infectious disease that continues to greatly impact morbidity and mortality worldwide; in 2011 it caused 1.4 million deaths.
Ruffner, Megan, Hay, Charles, Crawford, Zachary, Wilin, Kent, Roecker, Andrew   +4 more
core   +1 more source

Bedaquiline and tuberculosis workshop 30 June 2023 full transcript 09oct2023

Transcript of webinar held on 30th June 2023 "Bedaquiline and Tuberculosis (TB): What might the future hold?" (https://www.ucl.ac.uk/tb/bedaquiline-and-tb-what-might-future-hold; https://www.youtube.com/watch?v=vQJolt6ebkc). There has been minor editing,
Neil Stoker (10247273)
core   +1 more source